Protocol Ledger

NCT05858853 · Phase II/III · COMPLETED

Phase II/III of Recombinant Human Serum Albumin

Interventional Phase II/III clinical trial protocol NCT05858853 sponsored by Beijing Protgen Biotechnology Development Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-05-24 Enrollment: 92 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05858853
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)92 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05858853
Protocol FieldVerified Registry Value
NCT IdentifierNCT05858853
Consolidated Lead SponsorBeijing Protgen Biotechnology Development Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment92 participants (ACTUAL)
Registered Start Date2023-05-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05858853
Hospital Research SiteLocationSite Profile
Beijing Friendship Hospital , Capital Medical UniversityBeijing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI